Patent Information Sample Clauses
The Patent Information clause defines the obligations of parties to disclose or provide information regarding patents relevant to the subject matter of the agreement. Typically, this clause requires each party to inform the other about any existing or pending patents that may affect the use, development, or commercialization of products or technologies covered by the contract. By ensuring transparency about patent rights, the clause helps prevent inadvertent infringement and clarifies the intellectual property landscape, thereby reducing legal risks and fostering informed decision-making.
Patent Information. Licensee acknowledges that it has previously received copies of all patents and patent applications comprising the Patent Rights. Pursuant to this Agreement, all information and correspondence relating to the Patent Rights received from University or University's patent counsel is considered the University's Confidential Information, whether or not marked as confidential.
Patent Information. The applicant must comply with the patent informa- tion requirements under section 512(c)(3) of the act.
Patent Information. For each Patent Right for which Takeda assumes the Prosecution, maintenance, and enforcement activities pursuant to Section 13.9.2(e) (Prosecution Responsibilities), Licensee, if requested in writing by Takeda, will provide, at Takeda’s expense, any and all (i) material correspondence with the relevant Patent Offices pertaining to Licensee’s prosecution of the Takeda Patent Rights, and Licensee’s interest in the Joint Patent Rights, in each case to the extent pertaining to the Terminated Products and not previously provided to Takeda during the course of the Agreement and (ii) a report detailing the status of all Licensee Patent Rights, Takeda Patent Rights, and Joint Patent Rights at the time of termination or expiration; provided that if such termination relates to a particular Terminated Field for the TAK-385 Licensed Compound, then the foregoing obligations shall apply with respect to any such Patent Rights that have Valid Claims Covering the Exploitation of the TAK-385 Licensed Compound and TAK-385 Licensed Products in the Terminated Field.
Patent Information. GSK, if requested in writing by Surface, will provide any (i) material correspondence with the relevant patent offices pertaining to GSK’s Prosecution of the Licensed Patents, the Joint Patents and the European Opposition Proceeding to the extent not previously provided to Surface during the course of the Agreement and (ii) a report detailing the status of all Licensed Patents, Joint Patents and the European Opposition Proceeding at the time of termination.
Patent Information. ▇▇▇▇▇▇▇, if requested in writing by Odyssey, will provide any (a) material correspondence with the relevant patent offices pertaining to ▇▇▇▇▇▇▇’▇ Prosecution of the Prosecution Patents to the extent not previously provided to Odyssey during the course of this Agreement and (b) a report detailing the status of all such Prosecution Patents at the time of termination.
Patent Information. The Company’s algorithm, methods, and technologies embedded in this Web site are already covered by patents or are patent pending.
Patent Information. DRC shall cause a copy of the formulation of the Patent to be duplicated and deposited with DRC's counsel, Ehmann, Van Denbergh & Trainor, P.C., ▇▇ or before Decembe▇ ▇▇, ▇001.
Patent Information. 12 5.14 Invoicing ............................................ 12 5.15 Title and Risk of Loss ............................... 12 5.16 Monthly Statements; Payment .......................... 12 5.17
Patent Information. The Product packaging shall identify all patents and pending patent applications under which the Product is manufactured by ORTHOBIO.
Patent Information. In the event of termination of this Agreement in its entirety, GEHC, if requested in writing by LMI, will, at LMI’s cost and expense, provide (i) material correspondence, as determined in GEHC’s sole discretion, with the relevant patent offices pertaining to GEHC’s prosecution of the LMI Patent Rights, LMI Services Assigned Patent Rights, GEHC Improvement Patent Rights, and Joint Patent Rights in the Territory (or, where such termination relates to a Terminated Country, solely in such Terminated Country), to the extent not previously provided to LMI during the course of the Agreement, and (ii) a report reasonably detailing the status of all LMI Patent Rights, LMI Services Assigned Patent Rights, GEHC Improvement Patent Rights, and Joint Patent Rights at the time of termination or expiration in the Territory (or, where such termination relates to a Terminated Country, solely in such Terminated Country), to the extent not previously provided to LMI or known to LMI.